Oleamide MEA (85% Powder)
Oleoyl‑ethanolamide (OEA) food‑grade powder; typical 125 mg BID with RCT support for appetite/weight and oxidative‑stress markers.
oleoyl‑ethanolamide (OEA) — the monoethanolamide of oleic acid. That’s different from oleamide (simple amide; animal sleep lipid)
| Benefit |
Typical study dose* |
Key human findings |
High-quality sources |
| Appetite & weight |
250 mg/day (125 mg BID), 8 weeks |
↓ hunger, body weight, BMI, waist; ↑ PPAR‑α expression vs placebo. |
PubMed |
| Oxidative stress |
200–300 mg/day, 8–12 weeks |
↑ TAC, SOD; ↓ MDA, ox‑LDL. Cytokines mixed across trials. |
Frontiers 2023 |
| Lipids & glycemia |
250–300 mg/day, 8–12 weeks |
Signals for ↓ triglycerides and improved fasting glucose/HOMA‑IR (pooled analyses, needs more RCTs). |
BMC 2024, Frontiers 2025 |
*Common study pattern: ≥250 mg/day for ≥8 weeks.
Mechanistic highlights
- PPAR‑α agonist: Gut‑derived lipid produced during fat absorption; promotes satiety and fat utilization.
- Vagal signaling: Intestinal OEA signals to the brain to extend inter‑meal intervals.
- Metabolic effects: Influences lipid handling and oxidative‑stress pathways in human studies.
Safety & practical use
- Usual supplemental range: 125–300 mg/day (often 125 mg BID).
- Evidence grade: Moderate and evolving; best data for appetite/weight, oxidative‑stress markers.
- Interactions/medical advice: Advise oversight for pregnancy, chronic disease, or when on lipid/glucose‑active medication.
- Storage: Cool, dry, sealed; protect from light/moisture. Micro limits per COA.
| Mechanism |
- |
| Appearance |
- |
| Longevity |
- |
| Strength |
- |
| Storage |
- |
| Shelf Life |
- |
| Allergen(s) |
- |
| Dosage (Range) |
- |
| Recommended Dosage |
- |
| Dosage (Per Day) |
- |
| Recommended Dosage (Per Day) |
- |
| Mix Method |
- |
| Heat Resistance |
- |
| Stable in pH range |
- |
| Solubility |
- |
| Product Types |
- |
| INCI |
- |
